Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.39 |
| ▸ | METAP2 | P50579 | 8/20 | 0.37 |
| ▸ | METAP1 | P53582 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12746435 | 1.00 | MGAM (0.39) | MGAMGAASIMGAM2BTN3A1 | |
| SCHEMBL22300550 | 0.91 | BTN3A1 (0.36) | MGAMGAASIMGAM2BTN3A1 | |
| SCHEMBL13633863 | 0.88 | MGAM (0.39) | MGAMGAASIMGAM2BTN3A1 | |
| SCHEMBL19225388 | 0.87 | BTN3A1 (0.34) | MGAMGAASIMGAM2BTN3A1 | |
| SCHEMBL12746431 | 0.86 | BTN3A1 (0.39) | MGAMGAASIMGAM2BTN3A1 | |
| SCHEMBL14071817 | 0.84 | ACE (0.37) | BTN3A1METAP2METAP1 | |
| SCHEMBL27494852 | 0.83 | MGAM (0.39) | MGAMGAASIMGAM2BTN3A1 | |
| SCHEMBL20181544 | 0.83 | MGAM (0.39) | MGAMGAASIMGAM2BTN3A1 | |
| SCHEMBL28273778 | 0.83 | MGAM (0.39) | MGAMGAASIMGAM2BTN3A1 | |
| SCHEMBL20181801 | 0.82 | BTN3A1 (0.37) | MGAMGAASIMGAM2BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325931-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-10 | — | — | US | disclosed |
| US-20200399298-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | THE JOHNS HOPKINS UNIVERSITY | 2020-12-24 | — | — | US | disclosed |
| US-20200069706-A1 | PRODRUGS OF 2-PMPA FOR HEALTHY TISSUE PROTECTION DURING PSMA-TARGETED CANCER IMAGING OR RADIOTHERAPY | BAYER HEALTHCARE HOLDINGS LLC | 2020-03-05 | — | — | US | disclosed |
| US-10544176-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-01-28 | — | — | US | disclosed |
| US-9988407-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170226141-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325931-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | FOLH1, KLK3, DNPEP | MGAM 242/4885GAA 328/4885SI 392/4885 |
| US-20170226141-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | FOLH1, KLK3, DNPEP | MGAM 242/4885GAA 328/4885SI 392/4885 |
| US-20200399298-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | FOLH1, KLK3, DNPEP | MGAM 291/4885GAA 241/4885SI 335/4885 |
| US-20200069706-A1 | PRODRUGS OF 2-PMPA FOR HEALTHY TISSUE PROTECTION DURING PSMA-TARGETED CANCER IMAGING OR RADIOTHERAPY | PLPBP, PTMA, PTPA | MGAM 429/4885GAA 398/4885SI 210/4885 |
| US-10544176-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | FOLH1, KLK3, DNPEP | MGAM 242/4885GAA 328/4885SI 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.